Targeting adenosine A2A receptors in Parkinson's disease

Trends in Neurosciences

Volumn 29, Issue 11, 2006, Pages 647-654

  Schwarzschild, Michael A ^a   Agnati, Luigi ^b   Fuxe, Kjell ^b   Chen, Jiang Fan ^c   Morelli, Micaela ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; CAFFEINE; ISTRADEFYLLINE; LEVODOPA; SCH BT 2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DYSKINESIA; HUMAN; IMMUNOREACTIVITY; MUSCLE RIGIDITY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREMOR; ANIMAL; BIOLOGICAL MODEL; BRAIN; CORPUS STRIATUM; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; METABOLISM; METHODOLOGY;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CORPUS STRIATUM; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, NEUROLOGICAL; PARKINSON DISEASE; RECEPTOR, ADENOSINE A2A;

EID: 33750171348     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2006.09.004     Document Type: Review

References (75)

1. 2 receptors in the neostriatum. Brain Res. 594 (1992) 124-130
2. Ferré S., et al. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13 (1993) 5402-5406
3. 2 receptor interactions in the striatum as a basis for adenosine/dopamine interactions in the central nervous system. Drug Dev. Res. 28 (1993) 374-380
4. 1 agonists in dopamine-denervated rats. Eur. J. Neurosci. 8 (1996) 1176-1181
5. Pollack A.E., and Fink J.S. Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res. 743 (1996) 124-130
6. 2A receptor antagonism potentiates l-dopa-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 321 (1997) 143-147
7. 1 receptor-mediated effects on c-fos expression. J. Neurosci. 17 (1997) 8038-8048
8. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43 (1998) 507-513
9. 2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatment in 6-hydroxydopamine-lesioned rats. Synapse 39 (2001) 233-238
10. 2A receptor antagonist in MPTP-treated monkeys. Neurology 52 (1999) 1673-1677
11. 2A receptor antagonist treatment of Parkinson's disease. Neurology 61 (2003) 293-296
12. 2A receptor antagonist istradefylline in advanced PD. Neurology 61 (2003) 297-303
13. 2A receptor antagonists in Parkinson's disease. Pharmacol. Ther. 105 (2005) 267-310
14. 2A adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41 (2001) 160-171
15. 2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav. Brain Res. 148 (2004) 47-54
16. 2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp. Neurol. 189 (2004) 182-188
17. Schiffmann S.N., et al. The striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons. An in situ hybridization histochemistry study. J. Neurochem. 57 (1991) 1062-1067
18. Fink J.S., et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Mol. Brain Res. 14 (1992) 186-195
19. Pollack A.E., and Fink J.S. Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 68 (1995) 721-728
20. 2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 100 (2000) 53-62
21. Fredholm B.B., et al. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 385-412
22. Ross G.W., et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283 (2000) 2674-2679
23. Ascherio A., et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. 50 (2001) 56-63
24. Ascherio A., et al. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 60 (2003) 790-795
25. 2A adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21 (2001) RC143
26. 2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80 (2002) 262-270
27. Xu K., et al. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci. Lett. 322 (2002) 13-16
28. Xu K., et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 26 (2006) 535-541
29. 2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res. 705 (1995) 79-84
30. 2A receptor antagonist. Brain Res. 800 (1998) 328-335
31. 2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport 9 (1998) 3955-3959
32. 2A antagonists. J. Neurosci. 23 (2003) 5361-5369
33. 2A receptor attenuates 3-nitropropionic acid-induced striatal damage. J. Neurochem. 88 (2004) 538-544
34. Alfinito P.D., et al. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J. Neurosci. 23 (2003) 10982-10987
35. 2A receptor blockade of β-amyloid neurotoxicity. Br. J. Pharmacol. 138 (2003) 1207-1209
36. Dunwiddie T.V., and Masino S.A. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 24 (2001) 31-55
37. 2A adenosine receptors. Life Sci. 68 (2001) 1343-1350
38. 2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br. J. Pharmacol. 136 (2002) 434-440
39. 2A-receptors. Glia 18 (1996) 152-160
40. 2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat. Med. 10 (2004) 1081-1087
41. Pierri M., et al. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48 (2005) 517-524
42. 2A adenosine receptors. J. Neurosci. 22 (2002) 1054-1062
43. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184 (2003) 285-294
44. 2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J. Neurochem. 84 (2003) 1398-1410
45. Pinna A., et al. Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. Behav. Brain Res. 171 (2006) 175-178
46. Cenci M.A., et al. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10 (1998) 2694-2706
47. 2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata. Exp. Neurol. 184 (2003) 679-687
48. 2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology 61 Suppl. 6 (2003) S39-S43
49. Chase T.N., et al. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox. Res. 5 (2003) 139-146
50. 2A receptor knockout mice. Br. J. Pharmacol. 134 (2001) 68-77
51. 2A receptors. Annu. Rev. Immunol. 22 (2004) 657-682
52. 2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 61 Suppl. 6 (2003) S19-S23
53. Agnati L.F., et al. Receptor-receptor interactions, receptor mosaics, and basic principles of molecular network organization: possible implications for drug development. J. Mol. Neurosci. 26 (2005) 193-208
54. 2 heteromeric receptor complexes and their function. J. Mol. Neurosci. 26 (2005) 209-220
55. 2A receptors and dopamine D2 receptors. J. Biol. Chem. 277 (2002) 18091-18097
56. 2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278 (2003) 46741-46749
57. 2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Neurochem. 88 (2004) 726-734
58. 2 receptors in living cells. Biochem. Biophys. Res. Commun. 306 (2003) 544-549
59. 2A receptor antagonist. J. Neurosci. 20 (2000) 5848-5852
60. 2 receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1970-1975
61. 3 heteromeric complexes. Mol. Pharmacol. 67 (2005) 400-407
62. Nimchinsky E.A., et al. Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells. J. Biol. Chem. 272 (1997) 29229-29237
63. 2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology 38 (1999) 129-140
64. 2a receptors. Neuropsychopharmacology 25 (2001) 505-513
65. 5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11940-11945
66. 2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 92 (2005) 433-441
67. 2A receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1322-1327
68. 2 receptors. Neurosci. Lett. 324 (2002) 154-158
69. 5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29 (2004) 1451-1461
70. 2A receptors in normal and parkinsonian mice. J. Neurosci. 25 (2005) 10414-10419
71. Agnati L.F., et al. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev. 55 (2003) 509-550
72. Ciruela F., et al. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci. 26 (2006) 2080-2087
73. Tohyama M., and Takatsuji K. Atlas of Neuroactive Substances and Their Receptors in the Rat (1998), Oxford University Press
74. Obeso J.A., et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 23 (2000) S8-S19
75. 2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 16 (1996) 605-611